MLICM
APLS

Metropolitan Life Insurance Company (MetLife)’s Apellis Pharmaceuticals APLS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,066
Closed -$334K – 2463
2023
Q1 		$334K Sell
5,066
-697
-12% -$40.2K 0.02% 523
2022
Q4 		$298K Buy
5,763
+131
+2% +$6.95K 0.01% 570
2022
Q3 		$385K Buy
5,632
+150
+3% +$8.88K 0.02% 518
2022
Q2 		$248K Buy
5,482
+588
+12% +$26.8K 0.01% 631
2022
Q1 		$249K Sell
4,894
-13,512
-73% -$597K 0.01% 716
2021
Q4 		$870K Buy
18,406
+749
+4% +$29.5K 0.01% 1063
2021
Q3 		$582K Sell
17,657
-17,075
-49% -$959K 0.01% 1355
2021
Q2 		$2.2M Buy
34,732
+18,439
+113% +$951K 0.02% 914
2021
Q1 		$699K Sell
16,293
-860
-5% -$40.7K 0.01% 1199
2020
Q4 		$981K Sell
17,153
-1,187
-6% -$50.2K 0.01% 895
2020
Q3 		$553K Hold
18,340
– – 0.01% 1151
2020
Q2 		$599K Buy
18,340
+134
+0.7% +$4.3K 0.01% 1071
2020
Q1 		$488K Buy
18,206
+2,076
+13% +$73.7K 0.01% 1058
2019
Q4 		$494K Hold
16,130
– – 0.01% 1333
2019
Q3 		$389K Buy
16,130
+3,071
+24% +$84.5K 0.01% 1446
2019
Q2 		$331K Buy
13,059
+843
+7% +$17.2K 0.01% 1557
2019
Q1 		$238K Hold
12,216
– – ﹤0.01% 1781
2018
Q4 		$161K Hold
12,216
– – ﹤0.01% 1945
2018
Q3 		$217K Buy
+12,216
New +$226K ﹤0.01% 1950
2018
Q2 		– Sell
-4,020
Closed -$88.9K – 2449
2018
Q1 		$88.9K Buy
+4,020
New +$79K ﹤0.01% 2343

Other funds holding APLS

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s APLS Position: Q2 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Apellis Pharmaceuticals (APLS) in Q2 2023, closing a stake of 5,066 shares — an estimated $334K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in APLS in Q1 2018 and held it in 20 quarters. The position peaked at $2.2M in Q2 2021. 316 funds tracked by Wall St. Rank hold APLS as of Q2 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Apellis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 5,066 Apellis Pharmaceuticals shares in Q2 2023, an estimated $334K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Apellis Pharmaceuticals in Q1 2018 and held it in 20 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Apellis Pharmaceuticals position peaked at $2.2M in Q2 2021.
  • 316 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2023, filed 10 Aug 2023.